An interventional study of Metformin and Antidepressant Therapy in Depression, Depressive Disorder and Overweight or Obesity, sponsored by Riphah International University. Recruiting at 2 sites in Pakistan. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by Riphah International University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing metformin in Depression — 3 open to participants now, 3 under way, none of them phase 3. Metformin · Depression.
Among the 10 studies testing metformin in Depression, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2026, is one of 2 with no phase, and was the 10th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →3 of the 10 studies testing metformin in Depression are open now, in 2 countries. Recruiting first, the newest first:
Fazaia Ruth Pfau Medical College · Sites in Pakistan
Ages 18–45
Beni-Suef University · Sites in Egypt
Ages 45–60
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 71 across the 10 interventional studies. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 10 most frequent:
Riphah International University is the lead sponsor of 2,201 studies on the registry; 647 are open to participants now.
Riphah International University has 9 studies filed under Depression — fewer than ten, so there is no comparison to draw.
1 of the studies testing metformin in Depression that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654179Riphah International UniversityMetformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation | 2027-06-11 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing metformin in Depression, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1/RPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patients. Patients with certain variants may respond better or worse to antidepressants and may have different weight outcomes.
There is a substantial percentage of the Pakistani population who are both overweight/obese and depressed, with estimates from clinical samples averaging 25%. So, the personalized treatment approach for depression and obesity needs to be explored.
Obesity and depression commonly coexist and are associated with poorer health outcomes. Metformin, widely used for metabolic disorders and obesity, has shown potential antidepressant effects. However, evidence on its use as an adjunct to antidepressant therapy in patients with depression-obesity comorbidity remains limited, and the influence of genetic variants on treatment response is not well understood. This study aims to evaluate the effectiveness of adjunctive metformin and its association with NEGR1 and RPL31P12 genetic variants in this population.
INCLUSION CRITERIA Group I: Normal Controls Group II: Depression Group III: Obesity
Group IV and V:
EXCLUSION CRITERIA Groups I-III: Negative Controls (Normal: no depression and Obesity for SNP comparison only)
Group IV: Positive Control (RCT patients)
The patient does not have:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tab Sertraline 50 mg/day or Cap Duloxetine 60 mg/day or Tab Bupropion XL 150-300 mg/day
Drug: Antidepressant Therapy
Tab Sertraline 50 mg/day + Metformin or Cap Duloxetine 60 mg/day + Metformin or Tab Bupropion XL 150-300 mg/day + Metformin
Drug: Metformin · Drug: Antidepressant Therapy
Tab 500-2000 mg/day (500 mg BD to 1000 mg BD)
Also known as: Trade names: Glucophage, Neodipar
Sertraline 50 mg/day or Duloxetine 60 mg/day or Bupropion XL 150-300 mg/day
Also known as: Sertraline hydrochloride, Bupropion hydrochloride,
Change in Severity of the depression
The change in the total PHQ-9 score between baseline and 4-weeks follow-up is the primary outcome measure. This measure is a patient-rated inventory of depressive symptoms. All items are scored on scales ranging from 0-3 and the sum of the scores provides the total score for the measure. On this scale, higher scores indicate poorer outcomes. Scores 9-19 and 20-27 are considered moderate and severe depression respectively.
Time frame: 1 month
Change in BMI
Change in Body Mass Index (BMI): BMI will be measured at baseline and study completion and calculated as weight in kilograms divided by height in meters squared (kg/m²). The outcome will be assessed as the change in BMI from baseline. Asian BMI Classification: Underweight: \< 18.5 kg/m² Normal weight: 18.5-22.9 kg/m² Overweight: 23.0-24.9 kg/m² Obesity Class I: 25.0-29.9 kg/m² Obesity Class II: ≥ 30.0 kg/m² BMI reduction \< 1 kg/m²: Minimal change BMI reduction ≥ 1 kg/m²: Clinically meaningful improvement Weight loss ≥ 5% of baseline body weight: Clinically significant weight reduction associated with metabolic health benefits. A decrease in BMI from baseline and/or movement to a lower BMI category will be considered indicative of improvement in obesity-related outcomes.
Time frame: 3 months
Change in Blood Pressure
Change in Blood Pressure: Blood pressure will be measured in mmHg at baseline, 14 days, 28 days, one month and 3 months.. The outcome will be assessed as the change in systolic and diastolic blood pressure from baseline. Normal blood pressure is \<120/80 mmHg, elevated blood pressure is 120-129/\<80 mmHg, and high blood pressure is ≥130/80 mmHg. A reduction in blood pressure values from baseline will indicate improvement in cardiovascular health status.
Time frame: 3 months
Change in Blood Sugar Levels
Change in Blood Sugar: Blood glucose levels will be measured at baseline, 14 days, 28 days, one month and 3 months. The outcome will be assessed as the change in blood glucose from baseline. Normal fasting blood glucose is 70-99 mg/dL, prediabetes is 100-125 mg/dL, and diabetes is ≥126 mg/dL. A reduction in blood glucose levels toward the normal range will indicate improvement in glycemic control, whereas increase will be monitored for safety
Time frame: 3 months
Change in Renal Function tests
Change in Renal Function Tests: Renal function will be monitored by measuring serum creatinine and blood urea levels at baseline and study completion. The outcome will be assessed as the change in these parameters from baseline. Normal serum creatinine is approximately 0.6-1.2 mg/dL, while values \>1.2 mg/dL may indicate impaired renal function. Normal blood urea is approximately 15-40 mg/dL, while values \>40 mg/dL may suggest reduced kidney function or impaired renal clearance. An increase in serum creatinine or blood urea from baseline will be considered indicative of deterioration in renal function, whereas stable values within the normal range will indicate preserved renal function.
Time frame: 3 months
Change in Liver Function tests
Change in Liver Function Tests (LFTs): Liver function will be monitored at baseline and study completion. The outcome will be assessed as the change in liver enzyme levels and bilirubin from baseline. Alanine Aminotransferase (ALT): Normal 7-56 U/L; elevated \>56 U/L may indicate liver injury. Aspartate Aminotransferase (AST): Normal 10-40 U/L; elevated \>40 U/L may indicate hepatic or muscle injury. Alkaline Phosphatase (ALP): Normal 44-147 U/L; elevated \>147 U/L may suggest cholestatic liver disease or biliary obstruction. Total Bilirubin: Normal 0.2-1.2 mg/dL; elevated \>1.2 mg/dL may indicate impaired liver function or biliary obstruction. Albumin: Normal 3.5-5.0 g/dL; decreased \<3.5 g/dL may indicate impaired hepatic synthetic function.
Time frame: 3 months
C - Reactive Proteins levels
Change in C-Reactive Protein (CRP) Levels: CRP levels will be measured at baseline and study completion to assess systemic inflammation. The outcome will be assessed as the change in CRP levels from baseline. Normal: \< 3 mg/L Mildly elevated: 3-10 mg/L Moderately elevated: 10-50 mg/L Markedly elevated: \> 50 mg/L Severely elevated: \> 100 mg/L Decrease in CRP level: Indicates reduction in systemic inflammation. Stable CRP within normal range (\< 3 mg/L): Indicates absence of significant inflammation. Increase in CRP above normal range: Suggests worsening or persistent inflammatory activity.
Time frame: 3 months
Lipid Profile
It will be measured at baseline and study completion to monitor safety of combination therapy. Total Cholesterol (TC): Desirable: \< 200 mg/dL, Borderline high: 200-239 mg/dL, High: ≥ 240 mg/dL Low-Density Lipoprotein Cholesterol (LDL-C): Optimal: \< 100 mg/dL, Near optimal: 100-129 mg/dL, Borderline high: 130-159 mg/dL, High: 160-189 mg/dL, Very high: ≥ 190 mg/dL High-Density Lipoprotein Cholesterol (HDL-C): Low: \< 40 mg/dL (men), \< 50 mg/dL (women), Protective: ≥ 60 mg/dL Triglycerides (TG): Normal: \< 150 mg/dL, Borderline high: 150-199 mg/dL, High: 200-499 mg/dL, Very high: ≥ 500 mg/dL Interpretation: Decrease in TC, LDL-C, and TG levels indicates improvement in lipid metabolism. Increase in HDL-C levels indicates a favorable cardiovascular risk profile. Lipid values remaining within the normal range throughout the study will be considered indicative of metabolic safety of the combination therapy.
Time frame: 3 months
NEGR1 Polymorphism
To identify genetic polymorphism in NEGR1 in the Pakistani population, genetic polymorphism in NEGR1 in the Pakistani population will be assessed by ARMS PCR assay.
Time frame: 1 month
RPL31P12
To identify genetic polymorphism in RPL31P12 in the Pakistani population, genetic polymorphism in RPL31P12 in the Pakistani population will be assessed by ARMS PCR assay.
Time frame: 1 month
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 11 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Riphah International University →